Results
|
|
3641.
|
|
|
|
3642.
|
|
|
|
3643.
|
|
|
|
3644.
|
|
|
|
3645.
|
|
|
|
3646.
|
|
|
|
3647.
|
|
|
|
3648.
|
|
|
|
3649.
|
|
|
|
3650.
|
|
|
|
3651.
|
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. [electronic resource] by
- Larue, Ruben T H M
- Van De Voorde, Lien
- Berbée, Maaike
- van Elmpt, Wouter J C
- Dubois, Ludwig J
- Panth, Kranthi M
- Peeters, Sarah G J A
- Claessens, Ann
- Schreurs, Wendy M J
- Nap, Marius
- Warmerdam, Fabiënne A R M
- Erdkamp, Frans L G
- Sosef, Meindert N
- Lambin, Philippe
Producer: 20170926
In:
BMC cancer vol. 16
Availability: No items available.
|
|
|
3652.
|
|
|
|
3653.
|
|
|
|
3654.
|
|
|
|
3655.
|
|
|
|
3656.
|
|
|
|
3657.
|
|
|
|
3658.
|
|
|
|
3659.
|
|
|
|
3660.
|
|